10000 - 3H Pharmaceuticals
Latest Information Update: 22 Jan 2025
Price :
$50 *
At a glance
- Originator 3H Pharmaceuticals
- Class Antibodies; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Dec 2024 Preclinical trials in Cancer in China (Parenteral) (3H Pharmaceuticals pipeline; December 2024)